UK FF Nominees takes 1.4% stake in Agplus Holdings, a medical diagnostics firm
Published
UK FF Nominees Ltd entered Agplus Holdings with a 1.4% stake in ordinary shares. Other non-individual holders also increased their positions during a broader capital increase. The changes span a multi-year period, from the twenty-first of April 2021 to the twelfth of May 2026, with the filing dated the eighth of June 2026.
Shareholder data
Source: Companies House confirmation statement (CS01) — period to , filed .
Changes in this confirmation statement
| Type | Shareholder | Shares | Change | Share classes |
|---|---|---|---|---|
| New shareholder | THE INNOVATION & SCIENCE SEED FUND LP | 5,051,970 | — | C DEFERRED 5,051,970 |
| New shareholder | SUZHOU FEN RUI BIOLOGICAL MEDICAL ENGINEERING CO. LTD | 3,987,720 | — | C DEFERRED 3,987,720 |
| Increased | GTL INVESTMENTS LTD | 11,309,400 | +11698% | C DEFERRED 9,495,140 ORDINARY 1,814,260 |
| Increased | CORPORATION ONE LIMITED | 900,000 | +12400% | C DEFERRED 712,800 ORDINARY 187,200 |
| Increased | THE UK INNOVATION & SCIENCE SEED FUND LP | 288,586 | +466% | ORDINARY 288,586 |
Current shareholders (12)
| Shareholder | Total shares | Share classes |
|---|---|---|
| CHASE NOMINEES LIMITED - A/CJPMELA12 | 15,887,322 | C DEFERRED 15,887,322 |
| GTL INVESTMENTS LTD | 11,309,400 | ORDINARY 1,814,260 C DEFERRED 9,495,140 |
| THE INNOVATION & SCIENCE SEED FUND LP | 5,051,970 | C DEFERRED 5,051,970 |
| SUZHOU FEN RUI BIOLOGICAL MEDICAL ENGINEERING CO. LTD | 3,987,720 | C DEFERRED 3,987,720 |
| UK FF NOMINEES LTD | 1,596,380 | ORDINARY 1,596,380 |
| CHASE NOMINEES LIMITED - A/C JPMELAI2 | 1,427,446 | ORDINARY 1,427,446 |
| MNL NOMINEES LTD | 1,129,689 | C DEFERRED 1,129,689 |
| CORPORATION ONE LTD | 712,800 | C DEFERRED 712,800 |
| THE UK INNOVATION & SCIENCE SEED FUND LP | 288,586 | ORDINARY 288,586 |
| CORPORATION ONE LIMITED | 187,200 | ORDINARY 187,200 |
| MNL NOMINEES LIMITED | 103,266 | ORDINARY 103,266 |
| SUZHOU FEN RUI BIOLOGICAL MEDICAL ENGINEERING CO. LTD (FRBIOME) | 40,280 | ORDINARY 40,280 |
Contact the editorial team at editorial@fundingspotter.com